A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis
NCT03646604
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
Upadacitinib (ABT-494)
Sponsor
AbbVie